Your browser doesn't support javascript.
loading
Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center.
Suntsova, Elena V; Maschan, Alexey A; Baydildina, Dina D; Kalinina, Irina I; Petrova, Uliana N; Pshonkin, Alexey V; Novichkova, Galina A.
Afiliación
  • Suntsova EV; Dmitri Rogachev National Research Center for Pediatric Hematology, Oncology and Immunology, Moskva, Russia.
  • Maschan AA; Dmitri Rogachev National Research Center for Pediatric Hematology, Oncology and Immunology, Moskva, Russia.
  • Baydildina DD; Dmitri Rogachev National Research Center for Pediatric Hematology, Oncology and Immunology, Moskva, Russia.
  • Kalinina II; Dmitri Rogachev National Research Center for Pediatric Hematology, Oncology and Immunology, Moskva, Russia.
  • Petrova UN; Dmitri Rogachev National Research Center for Pediatric Hematology, Oncology and Immunology, Moskva, Russia.
  • Pshonkin AV; Dmitri Rogachev National Research Center for Pediatric Hematology, Oncology and Immunology, Moskva, Russia.
  • Novichkova GA; Dmitri Rogachev National Research Center for Pediatric Hematology, Oncology and Immunology, Moskva, Russia.
Pediatr Blood Cancer ; 66(6): e27704, 2019 06.
Article en En | MEDLINE | ID: mdl-30854783
We retrospectively analyzed sequential therapy with romiplostim and eltrombopag in 23 children with immune thrombocytopenia: switching from romiplostim to eltrombopag (10 patients) or vice versa (13 patients). The median age of patients at enrollment in the study was 5.6 years (2-15 years). Switching from romiplostim to eltrombopag was effective in eight (80%) patients, whereas switching from eltrombopag to romiplostim was effective in eight (62%) patients. The response rate was similar in patients failing the first thrombopoietin receptor agonist and those who had previous response. To date, all responders continue to maintain platelets over 50 × 109 /L at 13-39 months after switching.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirazoles / Trombopoyetina / Benzoatos / Proteínas Recombinantes de Fusión / Receptores Fc / Púrpura Trombocitopénica Idiopática / Receptores de Trombopoyetina / Centros de Atención Terciaria / Hidrazinas Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adolescent / Child / Child, preschool / Female / Humans / Male Idioma: En Revista: Pediatr Blood Cancer Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2019 Tipo del documento: Article País de afiliación: Rusia Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirazoles / Trombopoyetina / Benzoatos / Proteínas Recombinantes de Fusión / Receptores Fc / Púrpura Trombocitopénica Idiopática / Receptores de Trombopoyetina / Centros de Atención Terciaria / Hidrazinas Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adolescent / Child / Child, preschool / Female / Humans / Male Idioma: En Revista: Pediatr Blood Cancer Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2019 Tipo del documento: Article País de afiliación: Rusia Pais de publicación: Estados Unidos